CytoDyn extends $57M convertible notes maturity by 36 months, pays $1M/month in stock

CytoDyn Inc.

Note 1 ($28.5M) maturity extended to April 5, 2029; Note 2 ($28.5M) to April 23, 2029.
Monthly payment of $1M in common stock to noteholders priced at lower of prior close or 5-day average.
Annual interest rate on both notes reduced to 5% from prior rate as part of extension.
Total principal unchanged at $57M; company avoids immediate cash repayment through equity issuance.
Extension provides near-term liquidity relief but adds ongoing dilution for shareholders.

item 1.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

CytoDyn Inc. amended a notes offering (effective 2026-03-24).

Action: amendment
Agreement: notes offering
Effective: 2026-03-24

Exact text from the filing

On March 24, 2026, the Company and the holders of Note 1 and Note 2 (collectively, the “Noteholders”) agreed to extend the maturity date of each of the Notes by 36 months (the “Extension Periods”).

View on SEC.gov

299 material agreements filed in the last 30 days. Browse all material agreements →

CytoDyn Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-033943

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.